Cargando…

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. Phase I evaluation found a maximum tolerated rhizoxin dose of 2.6 mg m-2, with...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLeod, H. L., Murray, L. S., Wanders, J., Setanoians, A., Graham, M. A., Pavlidis, N., Heinrich, B., ten Bokkel Huinink, W. W., Wagener, D. J., Aamdal, S., Verweij, J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074819/ https://www.ncbi.nlm.nih.gov/pubmed/8980394

Ejemplares similares

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
por: Hanauske, A. R., et al.
Publicado: (1996)

Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.
por: Kaplan, S., et al.
Publicado: (1996)

Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
por: Verweij, J., et al.
Publicado: (1996)

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
por: Sternberg, C. N., et al.
Publicado: (1994)

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
por: Ciccolini, Joseph, et al.
Publicado: (2016)

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

Report of the EORTC-PAMM Meeting, Brussels, 16–18 March 2009: new strategies for a targeted and personalised therapy of cancer
por: Camporesi, S
Publicado: (2009)

PAMM and the ischemic cascade associated with radiation retinopathy
por: Wang, Derrick, et al.
Publicado: (2020)

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
por: de Wit, R., et al.
Publicado: (1998)

Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
por: Kerr, D. J., et al.
Publicado: (1995)

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
por: de Wit, R., et al.
Publicado: (1995)

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
por: Helgason, H H, et al.
Publicado: (2006)

Ring-Closing Metathesis Approaches towards the Total Synthesis of Rhizoxins
por: Liniger, Marc, et al.
Publicado: (2020)

Late PAMM-Like Lesions in a Patient with HIV Retinopathy
por: Kanakis, Menelaos, et al.
Publicado: (2023)

Comparative Pharmacology of Risperidone and Paliperidone
por: Corena-McLeod, Maria
Publicado: (2015)

Inhibition of Angiogenesis by Rhizoxin, a Microbial Metabolite Containing Two Epoxide Groups
por: Onozawa, Chizuko, et al.
Publicado: (1997)

Unfavourable expression of pharmacologic markers in mucinous colorectal cancer
por: Glasgow, S C, et al.
Publicado: (2005)

A short report: PAMM, a novel antioxidant protein, induced by oxidative stress
por: Xu, Yan, et al.
Publicado: (2015)

Circulating PAMM, a novel antioxidant and anti-inflammatory protein, is elevated in acute SCI
por: Morse, Leslie R., et al.
Publicado: (2020)

Parafoveal acute middle maculopathy (PAMM) in sickle cell disease after discontinuation of hydroxyurea
por: Parikh, Pooja, et al.
Publicado: (2022)

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
por: Cerny, T., et al.
Publicado: (1994)

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
por: Terwogt, J M M, et al.
Publicado: (1999)

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
por: Sulkes, A., et al.
Publicado: (1994)

Primary allogeneic mitochondrial mix (PAMM) transfer/transplant by MitoCeption to address damage in PBMCs caused by ultraviolet radiation
por: Cabrera, Francisco, et al.
Publicado: (2019)

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
por: Dercksen, M. W., et al.
Publicado: (1993)

In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.
por: McLeod, H. L., et al.
Publicado: (1996)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma
por: Arends, J J, et al.
Publicado: (2005)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
por: Elferink, F., et al.
Publicado: (1987)

Pharmacological Management of Agitation and Delirium in Older Adults: a Survey of Practices in Canadian Emergency Departments
por: Russek, Natanya S., et al.
Publicado: (2023)

Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21
por: Friend, E, et al.
Publicado: (2011)

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review
por: Engels, F K, et al.
Publicado: (2005)

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Autonomic pharmacology /
por: Broadley, Kenneth J.
Publicado: (1996)

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
por: Fosså, S. D., et al.
Publicado: (1995)

A randomised controlled trial of potential for pharmacologic prevention of new-onset albuminuria, hypertension and diabetes in a remote Aboriginal Australian community, 2008–2013
por: Hoy, Wendy E., et al.
Publicado: (2019)

Assessment of multiple pharmacological mechanisms in the ascaris sensitive sheep model of allergic asthma
por: Caniga, Michael, et al.
Publicado: (2013)

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
por: de Wit, R., et al.
Publicado: (1998)

The pathophysiological basis of pharmacological interventions in CAVD
por: Riem Vis, P. W., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lkccrr9aqnspl4iuvrfcfie18s